the patients entered into the medical research council 's first myelomatosis trial ( mrci ) have been followed up for a minimum of 12 years , and an attempt has been made to define features recorded at presentation that might predict long-term survival and to estimate the risk of acute myeloid leukaemia ( aml ) induced by treatment with either of the alkylating agents , melphalan or cyclophosphamide .
C0023467
acute myeloid leukaemia
C0010583
cyclophosphamide